Rise and shine, everyone, the middle of the week has arrived. And this calls for a celebratory cup or two of stimulation. How so? Well, you made it this far, which can be an accomplishment, after all. Moreover, there is always good reason to forge ahead, given that there is so much more to do and the effort just might pay off. With this in mind, we have assembled the usual menu of tidbits for your perusal. Hope you have a smashing day and do drop us a line when you run across something interesting …

Dr. Craig Thompson, the chief executive of Memorial Sloan Kettering Cancer Center, plans to resign his seats on the boards of Merck (MRK) and Charles River Laboratories (CRL), The New York Times reports. The decision is the latest fallout from a widening institutional reckoning over relationships between cancer center leaders and for-profit health care companies. Thompson, 65, received $300,000 in compensation from Merck in 2017, and was paid $70,000 in cash by Charles River last year, plus $215,050 in stock.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • In the matter of the final item, why do I seem to hear the Regeneron worthies say “Rats!” in reaction to this turn of events?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy